Fulcrum Therapeutics (FULC) Q1 2026 earnings summary

Executive summary

• Pociredir demonstrated robust increases in fetal hemoglobin, improved anemia and hemolysis markers, and encouraging reductions in vaso-occlusive crises in sickle cell disease patients in the PIONEER trial, with the 20 mg dose cohort showing significant efficacy as of December 2025.

• Pociredir was generally well-tolerated, with no treatment-related serious adverse events or discontinuations reported; a long-term safety and durability trial has been initiated.

• A registration-enabling trial for pociredir is planned for the second half of 2026, pending FDA feedback.

• The company discontinued its bone marrow failure syndromes program and terminated the CAMP4 license agreement to focus on core hematology programs.

• Appointed Dr. Josh Lehrer to the Board of Directors and announced CFO Alan Musso's retirement, with transition plans in place.

Financial highlights

• Ended Q1 2026 with $333.3 million in cash, cash equivalents, and marketable securities, down from $352.3 million at year-end 2025.

• Research and development expenses were $14.1 million in Q1 2026, up from $13.4 million in Q1 2025, mainly due to higher employee compensation and stock-based compensation.

• General and administrative expenses rose to $8.1 million from $7.0 million year-over-year, driven by compensation and professional services.

• Net loss was $18.9 million in Q1 2026, compared to $17.7 million in Q1 2025.

• Other income, net, was $3.3 million, up from $2.7 million, due to higher average cash balances.

Outlook and guidance

• Cash runway is projected to fund operations into 2029 based on $333.3 million in liquidity and current operating plans.

• Update on next trial design for pociredir anticipated after the upcoming end-of-phase FDA meeting, with a full summary of the PIONEER study expected at a medical conference later in 2026.

• Additional funding will be needed for future growth and commercialization.